Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.
A Three-month Clinical Study to Assess the Gingivitis Effect of Various Dentifrices.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trial Manager
- Phone Number: 513-622-5362
- Email: combs.cs@pg.com
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L5N 6J2
- All Sum ResearchAll Sum Research Center Ltd.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be at least 18 years of age;
- Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
- Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial; If female of child-bearing potential, agree to use a medically approved method of birth control for the duration of the study. Acceptable methods of medically approved birth control include: at least 3 months of use of a hormonal birth control (including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant), double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Not applicable to females not of child-bearing potential (females who have undergone a sterilization procedure including hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior;
- If female and of child-bearing potential, agree to immediately inform the study investigator if they become pregnant;
- Have at least 20 gradable teeth;
- Have mild to moderate gingivitis with a range of 10 to 70% bleeding sites;
- Agree to return for scheduled visits and follow the study procedures;
- Agree to refrain from use of any non-study oral hygiene products for the duration of the study; regular floss users can continue to floss in their customary manner.
- Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study; and
- Agree to refrain from any oral hygiene the morning of each visit.
Exclusion Criteria:
- Having taken antibiotic, anti-inflammatory, or anticoagulant medications within 4 weeks of the baseline visit;
- Having any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, severe gingivitis, or advanced periodontal disease;
- Females of child-bearing potential who are not using a medically approved method of birth control (i.e., hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening) or who have not been using hormonal birth control for a minimum of 3 months prior to study enrollment;
- Taking medication that alters gingival appearance or gingival bleeding (e.g., calcium channel blockers, anticonvulsants, or immunosuppressants) within one month prior to study initiation;
- Regularly (>5x/week) using anti-gingivitis treatments (e.g., stannous fluoride toothpaste, or anti-gingivitis mouthwashes, such as those containing chlorohexidine) in the month prior to screening;
- Removable oral appliances;
- Fixed facial or lingual orthodontic appliances;
- Have a positive pregnancy test (Clearblue) at baseline or self-reported pregnancy during the study; ;
- Any diseases or condition that might interfere with the safe participation in the study according to the study investigator;
- Inability to undergo study procedures; and
- Allergic reactions to any of the study toothpastes and/or ingredients in the study toothpastes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Positive Control
0.454% stannous fluoride, 0.533% zinc citrate
|
Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 12 weeks (~3 months).
|
|
Experimental: Experimental #1
0.243% NaF with 0.1% Hops, Humulus lupulus extract [0.045% hops β-acids]
|
Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 12 weeks (~3 months).
|
|
Experimental: Experimental #2
0.243% NaF with 0.5% Hops, Humulus lupulus extract [0.225% hops β-acids]
|
Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 12 weeks (~3 months).
|
|
Active Comparator: Negative Control
0.76% Sodium Monofluorophosphate
|
Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 12 weeks (~3 months).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number Bleeding Sites
Time Frame: 4 weeks (~1 month) and 12 weeks (~3 months)
|
4 weeks (~1 month) and 12 weeks (~3 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Löe-Silness Gingivitis Evaluation
Time Frame: 4 weeks (~1 month) and 12 weeks (~3 months)
|
scored on a scale of 0-3; 0 Normal gingiva; 1 Mild inflammation - slight change in colour, slight edema.
No bleeding on probing; 2 Moderate inflammation - redness, edema, and glazing.
Bleeding on probing; 3 Severe inflammation - marked redness, edema.
Ulceration.
Tendency to spontaneous bleeding
|
4 weeks (~1 month) and 12 weeks (~3 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: All Sum Research, All Sum Research
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.